Preclinical work in Takegawa et al. demonstrated that T-DXd was effective in both HER2-expressing CRC cells without HER2 amplification and HER2-amplified gastric cancer cells, with different mechanisms of action. The gene discussed is ERBB2; the disease is gastric cancer.